Paris - Delayed Quote EUR

Valbiotis SA (ALVAL.PA)

3.9000 -0.0650 (-1.64%)
At close: April 26 at 5:35 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,391.0000
785.0000
298.0000
3,092.0000
Cost of Revenue
17.0000
18.0000
16.0000
4.0000
Gross Profit
4,374.0000
767.0000
282.0000
3,088.0000
Operating Expense
13,290.0000
12,792.0000
8,758.0000
6,458.0000
Operating Income
-8,916.0000
-12,025.0000
-8,476.0000
-3,370.0000
Net Non Operating Interest Income Expense
-221.0000
-288.0000
-206.0000
-421.0000
Pretax Income
-9,138.0000
-12,314.0000
-8,681.0000
-3,829.0000
Tax Provision
4.0000
-2.0000
--
--
Net Income Common Stockholders
-9,142.0000
-12,312.0000
-8,681.0000
-3,829.0000
Diluted NI Available to Com Stockholders
-9,142.0000
-12,312.0000
-8,681.0000
-3,829.0000
Basic EPS
-0.85
-1.21
-0.94
-0.52
Diluted EPS
-0.85
-1.21
-0.94
-0.52
Basic Average Shares
11,458.7130
10,114.7120
9,157.8400
7,452.9030
Diluted Average Shares
12,408.8610
10,114.7120
9,157.8400
7,452.9030
Total Operating Income as Reported
-8,917.0000
-12,026.0000
-8,475.0000
-3,407.0000
Total Expenses
13,307.0000
12,810.0000
8,774.0000
6,462.0000
Net Income from Continuing & Discontinued Operation
-9,142.0000
-12,312.0000
-8,681.0000
-3,829.0000
Normalized Income
-9,142.0000
-12,312.0000
-8,681.0000
-3,794.0000
Interest Income
--
1.0000
142.0000
--
Interest Expense
228.0000
227.0000
229.0000
421.0000
Net Interest Income
-221.0000
-288.0000
-206.0000
-421.0000
EBIT
-8,910.0000
-12,087.0000
-8,452.0000
-3,408.0000
EBITDA
-8,342.0000
-11,235.0000
-7,511.0000
-2,371.0000
Reconciled Cost of Revenue
17.0000
18.0000
16.0000
4.0000
Reconciled Depreciation
568.0000
852.0000
941.0000
1,037.0000
Net Income from Continuing Operation Net Minority Interest
-9,142.0000
-12,312.0000
-8,681.0000
-3,829.0000
Total Unusual Items Excluding Goodwill
--
--
--
-35.0000
Total Unusual Items
--
--
--
-35.0000
Normalized EBITDA
-8,342.0000
-11,235.0000
-7,511.0000
-2,336.0000
Tax Rate for Calcs
0.0003
0.0000
--
--
12/31/2020 - 6/7/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALINT.PA IntegraGen SA
0.5900
-1.67%
 
ADOC.PA Adocia SA
8.43
+4.46%
 
ALSEN.PA Sensorion SA
0.7060
-0.56%
 
ALCOX.PA Nicox S.A.
0.3740
-0.27%
 
OSE.PA OSE Immunotherapeutics SA
5.56
-0.71%
 
NANO.PA Nanobiotix S.A.
5.45
+0.93%
 
GLMD Galmed Pharmaceuticals Ltd.
0.3916
+0.90%
 
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%